SEC Filings
Alector Books $162.9 Million In Revenue As GSK Exit Reshapes Its Drug Pipeline
A $100 million Genentech payment and an October share sale are expected to help fund operations into the second half of 2029.
Alector (ALEC) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
A $100 million Genentech payment and an October share sale are expected to help fund operations into the second half of 2029.
SEC Filings
The biotech investor says in a passive ownership filing it holds the stake with no aim of changing or influencing control of Alector.
SEC Filings
The Greenwich-based adviser and an affiliated fund hold 12,772,152 Alector shares, with no aim of influencing control.
SEC Filings
The biotech set a $75.0 million gross offering price above Thursday's last reported sale of $1.91, with Morgan Stanley and BTIG leading.
SEC Filings
The $2.05 price sits about 7.3% above the October 15 close, and Alector says it will fund research, manufacturing and possible deals.
SEC Filings
Exercising early still costs the old strike, which ranged from $6.48 to $33.11, under the retention terms the board set.
SEC Filings
The company says the deal lifts pro forma cash to about $223.7 million, enough to fund operations into 2029.